

ESMO Breast Cancer 2025 Industry Satellite Symposium

Friday 16 May 2025 12:15 – 13:15

Room 13

ICM-International Congress Center of the Messe Munich

# Overcoming barriers in MBC: Advancing oral SERDs for HR+, HER2- MBC

| Time (CEST) | Topic   | Speaker                 |
|-------------|---|-------------------------|
| 12:15–12:20 | Welcome & introduction  | Patrick Neven (Belgium) |
| 12:20–12:28 | Navigating challenges: Addressing unmet needs in MBC                                      | Patrick Neven (Belgium) |
| 12:28–12:40 | From current standards to future innovations: Exploring SERDs in HR+, HER2- MBC           | Komal Jhaveri (US)      |
| 12:40–12:50 | Refining precision: Strategies and best practices for biomarker testing in HR+, HER2- MBC | Ramona Erber (Germany)  |
| 12:50–13:15 | Views from the clinic: Q&A discussion   | All                     |

## Objectives

- Appraise the limitations of current endocrine therapies and analyse the evidence for why oral SERDs are needed in patients with HR+, HER2- MBC who progress on endocrine therapy
- Evaluate recent clinical data for current and emerging oral SERDs in patients with HR+, HER2- MBC
- Identify best practices for biomarker testing in the early detection and monitoring of actionable mutations and implications for treatment planning



**Patrick Neven**  
University Hospitals Leuven,  
Leuven, Belgium



**Komal Jhaveri**  
Memorial Sloan Kettering  
Cancer Center, New York,  
NY, USA



**Ramona Erber**  
University of Regensburg,  
Regensburg, Germany